Skoulidis et al. divided KRAS-mutant lung adenocarcinoma into three subgroups on account of concomitant co-mutations, namely STK11/LKB1 mutations (KL subgroup), TP53 mutations (KP subgroup), and (KRAS-only subgroup) and revealed that KL subgroup responded poorly to ICIs, with an objective response rate (ORR) of only 7.4% [4]. This evidence concerns the gene KRAS and lung adenocarcinoma.